obesity
Washington (AFP) - The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage. Wegovy, produced by Danish pharmaceutical giant Novo Nordisk, was approved "to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight," the FDA said in a statement. The FDA's decision could be a game changer for the approximately 70 percent of American adults who it says are either obese or ...
AFP
Washington (AFP) - Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity. "I would work out sometimes three times a day, I was doing hours worth of classes. I was eating really, really clean… and nothing was changing" the 36-year-old esthetician told AFP in a recent interview. "I heard about Ozempic for a while and then you start to see other people doing it like celebrities and then dropping weight super fast," she said. Fearing gastrointestinal iss...
AFP
Washington (AFP) - The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful -- and lucrative -- new obesity medicines. It is expected to be available in the United States within weeks, joining the likes of Novo Nordisk's successful Ozempic and Wegovy, and is widely expected to become a bestseller. JPMorgan analysts have predicted annual sales for so-called GLP-1 drugs to reach $140 billion by 2032, with the market dominated by Novo and Lilly. Administered by weekly injec...
AFP
Washington (AFP) - Drugs like Ozempic, which have become increasingly popular for losing weight, heighten the risk of certain severe gastrointestinal problems including stomach paralysis, according to a large study published Thursday. The paper, published in the Journal of the American Medical Association (JAMA), looked at a class of drugs called GLP-1 agonists that includes the brands Wegovy, Ozempic, Rybelsus and Saxenda. It then compared the rate of serious side effects to another class of weight loss drug, bupropion-naltrexone. The GLP-1 agonists were associated with an almost four times ...
AFP
Mexico City (AFP) - US cereal giant Kellogg's has been sanctioned by the Mexican authorities for breaking sugar and other content labeling rules in a country with one of the world's most obese populations. Around 380,000 boxes of Corn Flakes and other Kellogg's cereals have been blocked from sale, Federal Consumer Prosecutor's Office (Profeco) spokesman Jesus Montano told AFP on Tuesday. "They cannot market them like that," he said. The products fail to clearly warn consumers about excess calories and added sugar content, according to Profeco. "The national regulation requires that nutritional...
AFP
Washington (AFP) - The number of US states where at least 35 percent of residents are obese rose to 16 last year, with notable ethnic and racial disparities, new data from the Centers for Disease Control and Prevention (CDC) showed Wednesday. The states are mainly in the country's South and Midwest, and the total figure is up from nine in 2018 and 12 in 2019. The research comes via self-reporting from telephone surveys, and defines obesity as a body mass index BMI of 30 and over. Having obesity puts people at risk for many other serious chronic diseases including heart disease, stroke, type 2 ...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら